Nephron Research downgraded Inspire Medical (INSP) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Equal Weight from Overweight at Wells Fargo
- Inspire Medical downgraded to Neutral from Outperform at Baird
- Closing Bell Movers: Cisco falls 7% after earnings
- Inspire Medical Updates Governance, Outlines 2026 Growth Outlook
- Inspire Medical reports Q4 adjusted EPS $1.65, consensus 68c